With global health services increasingly worried about the rise of antibiotic-resistant diseases, researchers at Maynooth University have discovered a compound whose anti-MRSA qualities pave the way for the development of a new class of antibiotics The majority (64%) of the hospital-acquired infections are caused by either Staphylococcus aureus or E. coli. The situation has become worse with the advent of drug resistant strains of both the organisms. Methicilin-resistant Staphylococcus aureus (MRSA) has recently become the major threat to the world health scenario.
One of the last resort to treat nosocomial infection was the antibiotic vancomycin. The resistance of the "superbugs" to vancomycin is also being reported from different parts of the world. To add to this crisis, there is almost no innovation in the field of developing new antibiotic for the past three decades. In this…
